Lin Yuhui, Dai Wenjun, Chen Yongquan, He Xiaoqing, Xu Yunhong
Department of Cardiology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Front Physiol. 2022 Sep 19;13:1011048. doi: 10.3389/fphys.2022.1011048. eCollection 2022.
This study aimed to evaluate the value of neutrophil-to-platelet ratio (NPR) in predicting all-cause mortality in patients with ST-elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI). We enrolled 186 patients with STEMI who underwent primary PCI in the Third Affiliated Hospital of Guangzhou Medical University between January 2017 and December 2018. Based on the NPR values, the patients were divided into two groups: the NPR >0.035 group (n = 82) and the NPR ≤0.035 group (n = 104). All-cause mortality of the patients was followed up for 3 years. By the end of 3 years, 109 (58.6%) patients survived, 53 (28.5%) died, and 24 (12.9%) were lost to follow-up. Univariate analyses found that NPR was associated with all-cause mortality ( < 0.05). In COX regression analyses, patients in the high NPR group had a higher risk of all-cause death than those in the low NPR group (HR = 2.296, 95% CI: 1.150-4.582). These results indicate that NPR could predict all-cause death in 3 years after primary PCI in patients STEMI. NPR values may be useful in risk stratification and in specifying individualized treatment in patients with STEMI. In addition, NPR is a low-cost and easily accessible indicator, if its strong predictive value is confirmed in further studies of other large populations, it can be introduced into clinical practice for effective application.
本研究旨在评估中性粒细胞与血小板比值(NPR)在预测ST段抬高型心肌梗死(STEMI)患者直接经皮冠状动脉介入治疗(PCI)后全因死亡率中的价值。我们纳入了2017年1月至2018年12月期间在广州医科大学附属第三医院接受直接PCI的186例STEMI患者。根据NPR值,将患者分为两组:NPR>0.035组(n = 82)和NPR≤0.035组(n = 104)。对患者的全因死亡率进行了3年的随访。到3年结束时,109例(58.6%)患者存活,53例(28.5%)死亡,24例(12.9%)失访。单因素分析发现NPR与全因死亡率相关(<0.05)。在COX回归分析中,高NPR组患者全因死亡风险高于低NPR组(HR = 2.296,95%CI:1.150 - 4.582)。这些结果表明,NPR可以预测STEMI患者直接PCI后3年内的全因死亡。NPR值可能有助于STEMI患者的风险分层和制定个体化治疗方案。此外,NPR是一种低成本且易于获取的指标,如果在其他大样本人群的进一步研究中证实其具有较强的预测价值,可引入临床实践进行有效应用。